Literature DB >> 1617073

Nosocomial bacteremia due to Enterococcus faecalis without endocarditis.

W Graninger1, R Ragette.   

Abstract

During a 2-year observation period at a 2,200-bed university hospital, bacteremia due to Enterococcus faecalis was observed in 111 patients. Fifty-five patients with nosocomial bacteremia due to E. faecalis could be evaluated. The most common entry sites were the urinary tract (25%), the intraabdominal cavity (13%), and burn and decubital wounds (11%). Bacteremia was preceded by administration of cephalosporins, imipenem, and aztreonam (n = 39); ciprofloxacin (n = 11); and other antibiotics (n = 4). Age, sex, underlying disease, portal of entry, previous antibiotic therapy, and bacteremia due to other organisms had no influence on mortality. Treatment of bacteremia with penicillins (n = 45) and glycopeptides (n = 4) resulted in a mortality rate of 37%. The addition of a high-dose aminoglycoside to a penicillin did not result in a better survival rate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1617073     DOI: 10.1093/clinids/15.1.49

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Survival of Enterococcus faecalis in mouse peritoneal macrophages.

Authors:  C R Gentry-Weeks; R Karkhoff-Schweizer; A Pikis; M Estay; J M Keith
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 3.  Enterococcus faecium in hospitals.

Authors:  J J Wade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

Review 4.  Virulence of enterococci.

Authors:  B D Jett; M M Huycke; M S Gilmore
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

5.  Risk factors for enterococcal urinary tract infections: a multinational, retrospective cohort study.

Authors:  Adi Turjeman; Tanya Babich; Miquel Pujol; Jordi Carratalà; Evelyn Shaw; Aina Gomila-Grange; Cuong Vuong; Ibironke Addy; Irith Wiegand; Sally Grier; Alasdair MacGowan; Christiane Vank; Nienke Cuperus; Leo van den Heuvel; Leonard Leibovici; Noa Eliakim-Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-02       Impact factor: 3.267

6.  Low-dose Gentamicin for Uncomplicated Enterococcus faecalis Bacteremia May be Nephrotoxic in Children.

Authors:  Sarai Little Ibrahim; Long Zhang; Tammy M Brady; Alice J Hsu; Sara E Cosgrove; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2015-06-16       Impact factor: 9.079

7.  In Vitro evaluation of Enterococcus faecalis adhesion on various endodontic medicaments.

Authors:  Gloria Denotti; Rosaria Piga; Caterina Montaldo; Matteo Erriu; Francesca Pilia; Alessandra Piras; Massimo De Luca; Germano Orrù
Journal:  Open Dent J       Date:  2009-06-09

8.  Risk factors for acquiring ampicillin-resistant enterococci and clinical outcomes at a Canadian tertiary-care hospital.

Authors:  A E McCarthy; G Victor; K Ramotar; B Toye
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

9.  Colonization and infection with Enterococcus faecalis in intensive care units: the role of antimicrobial agents.

Authors:  M J Bonten; C A Gaillard; F H van Tiel; S van der Geest; E E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Clinical features, risk factors and outcomes of bacteremia due to enterococci with high-level gentamicin resistance: comparison with bacteremia due to enterococci without high-level gentamicin resistance.

Authors:  Hee-Chang Jang; Shinwon Lee; Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Nam Joong Kim; Eui-Chong Kim; Myoung-Don Oh; Kang Won Choe
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.